Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This study aims to determine whether dapaglfiflozin 12-week administration is associated with
a beneficial impact on the vasculature of patients with chronic kidney disease.